YAP signaling and liver fibrosis in people with HIV
Official title: YAP signaling in the pathogenesis of NAFLD in people living with HIV
Funded at Massachusetts General Hospital · NIH-11365056 · Data updated 2026-11-12
This project aims to understand how a cellular pathway called YAP drives liver disease in people living with HIV who have fatty liver and fibrosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 26, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $1,625,486 |
| NIH project number | 4R01DK138474-04 |
| Project ID | NIH-11365056 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults living with HIV who have NAFLD or NAFLD with fibrosis, especially those with liver-related progression risk.
✕Less likely to help
Patients without HIV or without NAFLD/NASH would not be the target of this study.
What this research studies
In people living with HIV, fatty liver disease progresses more quickly and can lead to serious liver damage. The study focuses on the YAP pathway, which controls cell growth and liver scarring, to see how it contributes to disease in the HIV context. Researchers will build on prior findings in humans and mouse models to explore how HIV infection and YAP signaling interact in the liver. Findings could identify new targets to slow or prevent fibrosis in PLWH with NAFLD. The work is conducted at Massachusetts General Hospital under the leadership of Dr. Raymond T. Chung over a five-year period.
Why it matters
Potential benefit: If successful, the research could lead to new ways to prevent or treat liver fibrosis in people living with HIV.
How similar studies have gone: Previous work supports a link between YAP signaling and liver fibrosis, with animal and human data suggesting promise for targeting this pathway.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Chung, Raymond T — Massachusetts General Hospital
- Study coordinator: Chung, Raymond T
Related research
Other NIH-funded projects on the same topics.
-
Lipid signals that control acetyl-CoA and fat metabolism in NAFLD
A study exploring how membrane lipids influence acetyl-CoA metabolism to understand and potentially treat nonalcoholic fatty liver disease (NAFLD).
-
Long-term study of NAFLD progression and gut bacteria in diverse groups
We’re following people over time to see how the gut microbiome and diet relate to fatty liver disease progression in diverse racial/ethnic groups.
-
Genetic and environmental risk for fatty liver cancer in Latinos (GENIAL)
A study to understand why Latino people with fatty liver disease might be more likely to develop liver cancer and to use genetic and environmental clues to predict who is at higher risk.
-
Toxic fats, vitamin B12 loss, and AHR may drive fatty liver disease
This grant looks at how certain environmental chemicals may trigger liver damage linked to fatty liver disease and how a vitamin found in the blood could be affected.
-
Role of cholesterol metabolism in toxin-driven liver disease
This grant explores how a liver toxin called TCDD affects cholesterol and fatty liver disease, and how a key enzyme (HMGCR) might change that risk in adults.
-
Small blood particle signals and fatty liver in children and teens
Researchers are looking at whether molecules carried in tiny blood particles can explain or signal fatty liver disease in children and adolescents with excess weight.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.